von Willebrand disease Medical Services in China

Von Willebrand disease (VWD) is the most common inherited bleeding disorder worldwide, affecting approximately 1% of the general population. It results from quantitative or qualitative defects in von Willebrand factor (VWF), a large multimeric glycoprotein essential for platelet adhesion to damaged vascular subendothelium and for stabilizing coagulation factor VIII (FVIII) in circulation. VWF mediates primary hemostasis by bridging platelets to exposed collagen at injury sites and acts as a carrier protein that protects FVIII from premature proteolysis—thus linking primary and secondary hemostasis. Pathogenically, VWD arises from mutations in the VWF gene on chromosome 12p13.3, leading to three major types: Type 1 (partial quantitative deficiency, ~75% of cases), Type 2 (qualitative defects with multiple subtypes—2A, 2B, 2M, 2N), and Type 3 (near-complete absence, rare but most severe). Inheritance is predominantly autosomal dominant for Types 1 and 2, while Type 3 follows autosomal recessive patterns. Epidemiologically, VWD affects all ethnic groups equally; however, diagnosis remains significantly under-recognized—especially in mild cases—due to variable expressivity, nonspecific symptoms, and lack of standardized global screening protocols. Prevalence estimates range from 0.6% to 1.3%, though only ~0.01% are clinically diagnosed, reflecting substantial diagnostic delay and undertreatment. Key risk factors include family history of mucocutaneous bleeding, consanguinity (particularly for Type 3), and female sex—menstruating individuals face heightened risks of menorrhagia, iron-deficiency anemia, and obstetric complications including postpartum hemorrhage. Quality of life impact is profound yet often underestimated: recurrent epistaxis, prolonged bleeding after dental procedures or minor trauma, easy bruising, and gastrointestinal bleeding contribute to chronic fatigue, anxiety around physical activity or surgery, school or work absenteeism, and psychosocial distress. Women frequently report diminished sexual health due to fear of menstrual or postcoital bleeding. Children may experience delayed diagnosis due to misattribution of symptoms to trauma or behavioral issues. Without appropriate prophylaxis or on-demand therapy, patients face increased morbidity during surgeries, childbirth, or invasive procedures—and in rare cases, life-threatening hemorrhage. Importantly, VWD is not merely a 'mild' bleeding disorder; its clinical heterogeneity demands individualized assessment using comprehensive testing—including VWF antigen (VWF:Ag), ristocetin cofactor activity (VWF:RCo), FVIII activity, and multimer analysis—to guide precise classification and management.

Von Willebrand disease (VWD) is the most common inherited bleeding disorder, affecting approximately 1% of the global population. It results from quantitative or qualitative defects in von Willebrand factor (VWF), a multimeric glycoprotein essential for platelet adhesion to subendothelial collagen and for stabilizing coagulation factor VIII (FVIII) in circulation. VWD is classified into three major types: Type 1 (partial quantitative deficiency, ~75% of cases), Type 2 (qualitative abnormalities with multiple subtypes—2A, 2B, 2M, 2N), and Type 3 (near-complete absence of VWF and markedly reduced FVIII, <1% of normal, most severe). Management is individualized based on type, severity, bleeding phenotype, and clinical context—including surgery, trauma, menstruation, or pregnancy.

Conservative treatment forms the cornerstone of VWD management, particularly for mild Type 1 disease. This includes avoidance of antiplatelet agents (e.g., aspirin, NSAIDs, clopidogrel), use of soft-bristled toothbrushes and dental floss alternatives to minimize gingival trauma, and prompt local measures for minor bleeding—such as direct pressure, nasal packing for epistaxis, and topical antifibrinolytics (e.g., tranexamic acid mouthwash). Patients are advised to maintain optimal hemostatic conditions through hydration, avoidance of vigorous physical activities associated with high injury risk (e.g., contact sports), and pre-emptive counseling before invasive procedures. Comprehensive patient education—delivered by hematologists and specialized nurses—is critical: patients must understand their diagnosis, recognize early signs of abnormal bleeding (e.g., prolonged menses >7 days, menorrhagia requiring >5 pads/tampons daily, postpartum hemorrhage, spontaneous joint or muscle bleeds), and carry medical identification. Regular follow-up every 6–12 months enables reassessment of bleeding score, laboratory parameters (VWF:Ag, VWF:RCo, FVIII:C), and psychosocial impact.

Pharmacologic therapy is stratified by VWD type and clinical scenario. Desmopressin (DDAVP), a synthetic vasopressin analog, remains first-line for responsive Type 1 and select Type 2A/2M patients. It stimulates endothelial release of stored VWF and FVIII, typically increasing levels 2–5-fold within 30–90 minutes; effects last 4–6 hours. Intravenous, subcutaneous, or intranasal formulations are used—though intranasal dosing may be less reliable in children <6 years or obese adults. DDAVP responsiveness must be confirmed via formal challenge testing prior to therapeutic use, especially before surgery. For DDAVP-unresponsive patients—including all Type 3, most Type 2B (risk of thrombocytopenia), and Type 2N (FVIII-binding defect)—plasma-derived VWF/FVIII concentrates (e.g., Humate-P®, Wilate®, Vonvendi®) are indicated. These products contain physiologically multimeric VWF and varying ratios of VWF:RCo to FVIII:C, enabling targeted correction of both primary hemostasis and intrinsic coagulation. Recombinant VWF (e.g., Vonvendi®) offers viral safety advantages and consistent pharmacokinetics but lacks ultra-large multimers in some preparations. Antifibrinolytic agents—tranexamic acid and epsilon-aminocaproic acid—are adjunctive therapies that inhibit plasmin-mediated clot lysis; they are especially effective for mucosal bleeding (menorrhagia, oral, gastrointestinal) and are often combined with replacement therapy perioperatively. Hormonal therapy (combined oral contraceptives or levonorgestrel-releasing intrauterine systems) is standard for gynecologic management of menorrhagia in reproductive-age women with VWD.

Surgical treatment is not curative but refers to procedural interventions requiring meticulous hemostatic planning. All elective surgeries—including dental extractions, tonsillectomy, orthopedic procedures, and cesarean delivery—mandate multidisciplinary coordination between hematologists, anesthesiologists, surgeons, and obstetricians. Preoperative assessment includes bleeding history, baseline VWF/FVIII assays, and DDAVP trial if appropriate. Perioperative protocols involve prophylactic VWF/FVIII concentrate infusion (targeting VWF:RCo ≥50–100 IU/dL and FVIII:C ≥80–100 IU/dL pre-incision, maintained for 3–10 days depending on wound vascularity), concomitant antifibrinolytics, and avoidance of tourniquets or electrocautery where possible. Minimally invasive techniques (e.g., laparoscopic cholecystectomy, hysteroscopic endometrial ablation) are preferred when feasible. In rare refractory cases—such as life-threatening hemorrhage unresponsive to conventional therapy—recombinant activated factor VII (rFVIIa) may be considered off-label, though evidence remains limited and thrombotic risk warrants caution.

Treatment advantages in China reflect rapid advancements in infrastructure, regulatory frameworks, and clinical expertise. Since 2018, China’s National Reimbursement Drug List (NRDL) has included plasma-derived VWF/FVIII concentrates and tranexamic acid, significantly improving accessibility and affordability. Major tertiary hospitals—especially those affiliated with Peking Union Medical College Hospital, Shanghai Ruijin Hospital, and West China Hospital—host accredited Hemophilia Treatment Centers (HTCs) with integrated multidisciplinary teams, real-time coagulation monitoring, and 24/7 on-call support. Domestic manufacturing of high-purity, solvent-detergent treated VWF concentrates (e.g., Shenzhen Kexing Biopharma’s product) ensures stable supply chains and reduces import dependency. Furthermore, China’s national VWD registry (launched 2021) facilitates epidemiologic research, genotype–phenotype correlation studies, and personalized dosing algorithms. Telehematology platforms now enable remote consultations and home infusion training across provinces, bridging urban–rural disparities. Clinical trials of novel extended-half-life VWF products and gene therapy vectors are actively recruiting in China, positioning the country at the forefront of next-generation therapeutics.

Recovery and long-term management emphasize sustained hemostatic protection and quality-of-life optimization. Post-procedure, patients require serial VWF/FVIII level monitoring (typically at 2, 6, 24, and 72 hours post-infusion), clinical assessment for bleeding recurrence or thrombosis, and gradual tapering of replacement therapy per protocol. Physical rehabilitation should commence only after hemostasis is confirmed—early mobilization is encouraged for surgical patients, but weight-bearing restrictions apply following orthopedic interventions. Psychosocial recovery includes counseling for anxiety related to bleeding episodes, fertility planning, and transition care for adolescents moving to adult hematology services. Annual screening for iron deficiency anemia (via ferritin and hemoglobin), liver/kidney function, and inhibitor development (rare but reported in Type 3) is recommended. Vaccination against hepatitis A and B is strongly advised given frequent exposure to plasma-derived products. Finally, genetic counseling and cascade testing of first-degree relatives ensure early diagnosis and preemptive management—critical for preventing complications such as chronic anemia, arthropathy, or postpartum hemorrhage. With comprehensive, individualized care, most individuals with VWD achieve near-normal life expectancy and functional capacity.